Literature DB >> 24846461

Silencing of Dicer1 temporally separates pro- and anti-apoptotic signaling and confers susceptibility to chemotherapy in p53 mutated cells.

Tatyana S Nekova1, Susanne Kneitz2, Hermann Einsele1, Gernot Stuhler1.   

Abstract

miRNAs are critically implicated in the initiation process of and progression through cancerogenesis. The mechanisms, however, by which miRNAs interfere with the signalosomes of human cancer cells, are still obscure. We utilized the p53-mutated human keratinocyte cell line HACAT to investigate the biological significance and extent to which miRNAs regulate proliferation, cell growth, and apoptosis in transformed phenotypes. Silencing of the miRNA-processing enzyme Dicer1 resulted in cell cycle arrest at the G1/S border, along with restoration of CDK inhibitor p21(CIP)expression. Employing a cell cycle-wide phospho-proteomic approach, we detected neglectable changes in abundance and schedule of overall and cell cycle periodic protein expression despite cell cycle arrest of Dicer1-depleted cells. Instead, we found substantially delayed post-translational modifications of some, but not all, signaling nodes. Phospho-site-specific analyses revealed that pro-apoptotic information elicited by Myc, β-catenin, and other mitotic pathways early in G1 are absorbed and balanced by anti-apoptotic signaling from AKT and NFκB in Dicer1-competent cells. The absence of regulatory miRNAs, however, led to a substantial delay of anti-apoptotic signaling, leaving pro-apoptotic stress unbalanced in Dicer1-deprived cells. We here show that this temporal separation of pro- and anti-apoptotic signaling induced by inhibition of Dicer1 is synergistic and synthetic lethal to low-dose 5-FU chemotherapy in p53-mutated HACAT cells. The findings reported here contribute to the understanding of the complex interactions of miRNAs with the signalosom of transformed phenotypes and may help to design novel strategies to fight cancer.

Entities:  

Keywords:  5-FU; Dicer; HACAT; apoptosis; cell cycle; miRNA; p21; p53; signaling pathway

Mesh:

Substances:

Year:  2014        PMID: 24846461      PMCID: PMC4111674          DOI: 10.4161/cc.29216

Source DB:  PubMed          Journal:  Cell Cycle        ISSN: 1551-4005            Impact factor:   4.534


  28 in total

1.  Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability.

Authors:  R Sears; F Nuckolls; E Haura; Y Taya; K Tamai; J R Nevins
Journal:  Genes Dev       Date:  2000-10-01       Impact factor: 11.361

Review 2.  An overview of MYC and its interactome.

Authors:  Maralice Conacci-Sorrell; Lisa McFerrin; Robert N Eisenman
Journal:  Cold Spring Harb Perspect Med       Date:  2014-01-01       Impact factor: 6.915

Review 3.  The noncanonical NF-κB pathway.

Authors:  Shao-Cong Sun
Journal:  Immunol Rev       Date:  2012-03       Impact factor: 12.988

Review 4.  Regulation of p53 by ING family members in suppression of tumor initiation and progression.

Authors:  Seyed Mehdi Jafarnejad; Gang Li
Journal:  Cancer Metastasis Rev       Date:  2012-06       Impact factor: 9.264

5.  Evaluation of an Actinomycin D/VX-680 aurora kinase inhibitor combination in p53-based cyclotherapy.

Authors:  Bhavya Rao; Ingeborg M M van Leeuwen; Maureen Higgins; Johanna Campbel; Alastair M Thompson; David P Lane; Sonia Lain
Journal:  Oncotarget       Date:  2010-11

6.  Cell cycle perturbation and acquired 5-fluorouracil chemoresistance.

Authors:  Xiaoxia Guo; Elisabeth Goessl; Gang Jin; Elaina S R Collie-Duguid; James Cassidy; Weiguang Wang; Vincent O'Brien
Journal:  Anticancer Res       Date:  2008 Jan-Feb       Impact factor: 2.480

Review 7.  Inteferons pen the JAK-STAT pathway.

Authors:  Christian Schindler; Courtney Plumlee
Journal:  Semin Cell Dev Biol       Date:  2008-08-26       Impact factor: 7.727

Review 8.  GSK-3beta regulates cyclin D1 expression: a new target for chemotherapy.

Authors:  Fumi Takahashi-Yanaga; Toshiyuki Sasaguri
Journal:  Cell Signal       Date:  2007-10-23       Impact factor: 4.315

9.  Specific activation of the p53 pathway by low dose actinomycin D: a new route to p53 based cyclotherapy.

Authors:  Meng Ling Choong; Henry Yang; May Ann Lee; David P Lane
Journal:  Cell Cycle       Date:  2009-09-13       Impact factor: 4.534

10.  Wt p53 impairs response to chemotherapy: make lemonade to spare normal cells.

Authors:  Mikhail V Blagosklonny
Journal:  Oncotarget       Date:  2012-06
View more
  2 in total

1.  Silencing of CDK2, but not CDK1, separates mitogenic from anti-apoptotic signaling, sensitizing p53 defective cells for synthetic lethality.

Authors:  Tatyana S Nekova; Susanne Kneitz; Hermann Einsele; Ralf Bargou; Gernot Stuhler
Journal:  Cell Cycle       Date:  2016-11-10       Impact factor: 4.534

Review 2.  Autophagy regulates death of retinal pigment epithelium cells in age-related macular degeneration.

Authors:  Kai Kaarniranta; Paulina Tokarz; Ali Koskela; Jussi Paterno; Janusz Blasiak
Journal:  Cell Biol Toxicol       Date:  2016-11-29       Impact factor: 6.691

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.